Publications Scientifiques et Présentations

Ces publications scientifiques et présentations sont proposées à des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de développement, et qui ne sont approuvés pour commercialisation par aucune autorité règlementaire ou de santé dans aucun pays du monde.

Publications importantes

Pongracic JA, Gagnon R, et al. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. doi: 10.1016/j.jaip.2021.11.017.

Bégin P, Bird JA, et al. Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy. Allergy. 2021. Dec;76(12):3835-3838. doi: 10.1111/all.15083.

Remington BC, Koppelman SJ, et al. Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: a novel approach to assessing relevance. Allergy. 2021. Oct;76(10):3223-3226. doi: 10.1111/all.14973.

Remington BC, Campbell DE, et al. Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results: Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. doi: 10.1016/j.anai.2020.11.015.

Brown-Whitehorn TF, de Blay F, et al. Sustained Unresponsiveness to Peanut After Long-term Peanut Epicutaneous Immunotherapy. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. doi: 10.1016/j.jaip.2020.08.017.

DunnGalvin A, Fleischer DM, et al. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. doi: 10.1016/j.jaip.2020.08.015.

Fleischer DM, Shreffler WG, et al. Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy For Peanut Allergy in Children: PEOPLE 3-Year Results. The Journal of Allergy and Clinical Immunology. 2020. doi:10.1016/j.jaci.2020.06.028.

Fleischer DM, Chinthrajah S, et al. An Evaluation of Factors Influencing Response to Epicutaneous Immunotherapy For Peanut Allergy in the PEPITES Trial. Allergy & Asthma Proceedings. 2020;41:1-10. doi:10.2500/aap.2020.41.200047. PMID: 32539908.

Fleischer DM, Spergel JM, et al. Evaluation of Daily Patch Application Duration For Epicutaneous Immunotherapy For Peanut Allergy. Allergy & Asthma Proceedings. 2020;41:278-284. doi:10.2500/aap.2020.41.200045. PMID: 32517847.

Greenhawt M, Kim EH, et al. Improvements in Eliciting Dose Across Baseline Sensitivities Following 12 Months of Epicutaneous Immunotherapy (EPIT) in Peanut-Allergic Children Aged 4 to 11 Years. The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. doi:10.1016/j.jaip.2020.05.030. PMID: 32502548.

Fleischer DM, Greenhawt M, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. doi:10.1001/jama.2019.1113. PMID: 30794314.

Sampson HA, Shreffler WG, et al. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. doi:10.1001/jama.2017.16591. PMID: 29136445.

Présentations Récentes

Ces résumés ont été approuvés pour présentation à un congrès médical et n’ont pas été soumis à une revue complète par des pairs.

American College of Allergy, Asthma & Immunology (ACAAI) 2021 Annual Scientific Meeting:

Oral Presentations:

  • REALISE (Real-life Use and Safety of EPIT) Study: 3 Year Results in Peanut-allergic Children – Terri F. Brown-Whitehorn, MD [Abstract D030]

Poster Presentations:

  • REALISE (Real-life Use and Safety of EPIT) Study: Health-related Quality of Life Changes During Treatment – Dareen Siri, MD [Abstract P116]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2022 Annual Meeting:

Poster Presentations:

  • Pooled Safety Data from Phase 3 Studies of Epicutaneous Immunotherapy for Peanut Allergy in Children Aged 4-11 Years – Rachel Robison, MD [Abstract 097]
  • Effect of Allergy Specialty Care of Healthcare Utilization Among Children with Peanut Allergy in the United States – Matthew Greenhawt, MD [Abstract 120]